-
公开(公告)号：US20220023438A1
公开(公告)日：2022-01-27
申请号：US17280800
申请日：2019-09-27
摘要： The present invention relates to a linker of the following formula (I) or a salt thereof: (I). The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof: (II). The present invention relates also to a binding unit-drug corrugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof: (III), (IV), as well as a pharmaceutical composition comprising such a binding unit-drug corrugate and its use in the treatment of cancer.
-
公开(公告)号：US20220105195A1
公开(公告)日：2022-04-07
申请号：US17454931
申请日：2021-11-15
发明人： Ian RILATT , Michel PEREZ , Liliane GOETSCH , Matthieu BROUSSAS , Charlotte BEAU-LARVOR , Jean-François HAEUW , Marie LAMOTHE
摘要： The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
-
公开(公告)号：US20240350657A1
公开(公告)日：2024-10-24
申请号：US18622613
申请日：2024-03-29
CPC分类号： A61K47/6889 , A61K38/07 , A61K38/12 , A61K47/545 , A61K47/68031 , A61K47/6809 , A61K47/6811 , A61K47/6849 , A61P35/00
摘要： The present invention relates to a linker of the following formula (I) or a salt thereof:
The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof:
The present invention relates also to a binding unit-drug conjugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof:
as well as a pharmaceutical composition comprising such a binding unit-drug conjugate and its use in the treatment of cancer.-
公开(公告)号：US20190202901A1
公开(公告)日：2019-07-04
申请号：US15771082
申请日：2016-10-26
发明人： Alexandra JOUHANNEAUD , Liliane GOETSCH , Matthieu BROUSSAS , Charlotte BEAU-LARVOR , Thierry CHAMPION , Robert ALAIN , Jean-François HAEUW , Ian RILATT , Michel PEREZ
CPC分类号： C07K16/22 , A61K47/65 , A61K47/6811 , A61K47/6849 , A61K47/6851 , A61P35/00
摘要： The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
-
公开(公告)号：US20200308242A1
公开(公告)日：2020-10-01
申请号：US16837916
申请日：2020-04-01
发明人： Peter LOWE , Jean-François HAEUW , Alicia CONTET , Céline BERTAUX , Barbara AKLA , Marie-Claire JANIN-BUSSAT
摘要： The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
-
公开(公告)号：US20190269788A1
公开(公告)日：2019-09-05
申请号：US16385597
申请日：2019-04-16
发明人： Ian RILATT , Michel PEREZ , Liliane GOETSCH , Matthieu BROUSSAS , Charlotte BEAU-LARVOR , Jean-François HAEUW , Marie LAMOTHE
IPC分类号： A61K47/68
摘要： The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.028 秒)
